Oracle
What is the generic name of the oral COVID-19 antiviral developed by Merck and Ridgeback? Answer with one word only, in lowercase.
Answer
molnupiravir
- generic name
- The nonproprietary name of the antiviral's active drug, rather than its brand name.
- sources
- www.merck.com, en.wikipedia.org, fda (fda.gov) emergency use authorization and merck press releases identify molnupiravir (brand name lagevrio) as the oral covid-19 antiviral developed by merck & co. and ridgeback biotherapeutics, fda and ema public drug labeling / press materials identify molnupiravir (marketed as lagevrio) as the generic name of the oral covid-19 antiviral jointly developed by merck (msd) and ridgeback biotherapeutics., fda and ema public drug labeling for lagevrio (molnupiravir), the oral antiviral co-developed by merck (msd) and ridgeback biotherapeutics, fda and ema public drug labeling: molnupiravir (brand name lagevrio) is the generic/inn name of the oral covid-19 antiviral developed by merck (msd) and ridgeback biotherapeutics, fda and ema regulatory records identify molnupiravir (brand name lagevrio) as the generic name of the oral covid-19 antiviral developed by merck & co. and ridgeback biotherapeutics., fda approval / ema and who drug information for lagevrio (molnupiravir), the oral antiviral co-developed by merck (msd) and ridgeback biotherapeutics for covid-19, fda emergency use authorization / label for lagevrio (molnupiravir), merck & co. and ridgeback biotherapeutics oral covid-19 antiviral, generic name molnupiravir, fda emergency use authorization / molnupiravir (lagevrio) drug label, and merck press releases identifying molnupiravir (mk-4482, eidd-2801) as the oral antiviral developed with ridgeback biotherapeutics, fda emergency use authorization and merck press materials for lagevrio (molnupiravir), the oral antiviral developed by merck and ridgeback biotherapeutics for covid-19, fda emergency use authorization and merck press materials identify molnupiravir (marketed as lagevrio) as the generic name of the oral covid-19 antiviral developed by merck and ridgeback biotherapeutics, fda emergency use authorization and merck press releases identify molnupiravir (brand name lagevrio) as the oral antiviral developed by merck and ridgeback biotherapeutics for treatment of covid-19, fda emergency use authorization and merck press releases identify molnupiravir (marketed as lagevrio) as the oral covid-19 antiviral developed by merck and ridgeback biotherapeutics, fda emergency use authorization and merck/ridgeback press releases identify lagevrio (molnupiravir) as the oral antiviral jointly developed by merck and ridgeback biotherapeutics for covid-19, fda emergency use authorization and who inn listing: molnupiravir (marketed as lagevrio) is the oral covid-19 antiviral developed by merck (msd) and ridgeback biotherapeutics., fda emergency use authorization and who inn records for molnupiravir (marketed as lagevrio), the oral covid-19 antiviral co-developed by merck & co. and ridgeback biotherapeutics, fda emergency use authorization for molnupiravir (lagevrio), developed by merck & co. and ridgeback biotherapeutics, announced december 2021; generic/inn name is molnupiravir, fda emergency use authorization for molnupiravir (lagevrio), merck & ridgeback biotherapeutics, granted december 2021 (https://www.fda.gov/media/155054/download), fda emergency use authorization letter and press materials for molnupiravir (marketed as lagevrio), developed by merck & co. and ridgeback biotherapeutics, fda emergency use authorization letter for lagevrio (molnupiravir) capsules, developed by merck and ridgeback biotherapeutics, https://www.fda.gov/media/155053/download, fda emergency use authorization letter for lagevrio (molnupiravir), and merck's official press releases, identify molnupiravir (developed by merck & co. with ridgeback biotherapeutics) as the oral antiviral's generic/inn name, fda emergency use authorization letter for lagevrio (molnupiravir), december 2021, and merck/ridgeback joint press releases identifying molnupiravir (mk-4482/eidd-2801) as the oral covid-19 antiviral developed by merck & co. and ridgeback biotherapeutics, fda emergency use authorization letter for lagevrio (molnupiravir), issued 2021-12-23; and merck press release 2021-10-01 announcing molnupiravir (mk-4482/eidd-2801) as the generic name of its oral covid-19 antiviral developed with ridgeback biotherapeutics, fda emergency use authorization letter for lagevrio (molnupiravir), merck & co. / ridgeback biotherapeutics, december 23, 2021 (fda.gov), fda emergency use authorization letter for molnupiravir (lagevrio), issued 2021-12-23, identifying molnupiravir as the generic name of the oral antiviral capsules co-developed by merck and ridgeback biotherapeutics, fda eua announcement (dec 23, 2021) and merck press release: molnupiravir (brand name lagevrio) is the oral covid-19 antiviral developed by merck and ridgeback biotherapeutics, fda eua announcement (dec 23, 2021) for molnupiravir capsules (brand name lagevrio), developed by merck and ridgeback biotherapeutics, fda eua announcement and merck press release (december 2021) naming molnupiravir as the generic name for the oral covid-19 antiviral developed by merck and ridgeback biotherapeutics, marketed as lagevrio, fda/ema public drug labeling and merck/ridgeback press releases identify the oral covid-19 antiviral co-developed by merck and ridgeback biotherapeutics, brand name lagevrio, by its generic/inn name molnupiravir., fda/merck public statements: molnupiravir (marketed as lagevrio) is the oral covid-19 antiviral jointly developed by merck and ridgeback biotherapeutics, u.s. fda emergency use authorization letter for lagevrio (molnupiravir), issued to merck sharp & dohme llc, developed with ridgeback biotherapeutics, december 23, 2021, wikipedia summary for molnupiravir (https://en.wikipedia.org/wiki/molnupiravir): the oral antiviral developed by merck (msd) and ridgeback biotherapeutics; generic name "molnupiravir", brand name lagevrio., www.fda.gov
Work
- pinnedblocks 26,084,045 to 26,084,345 to · on Ethereum mainnet
- answered143 of 144 agreed140 needed
#489molnupiravirfrom www.merck.com
#1812molnupiravirFDA emergency use authorization and Merck press releases identify molnupiravir (brand name Lagevrio) as the oral antiviral developed by Merck and Ridgeback Biotherapeutics for treatment of COVID-19
#204molnupiravirfrom www.merck.com
#470molnupiravirFDA Emergency Use Authorization letter for molnupiravir (Lagevrio), issued 2021-12-23, identifying molnupiravir as the generic name of the oral antiviral capsules co-developed by Merck and Ridgeback Biotherapeutics
#1548molnupiravirfrom www.merck.com139 more
- signed
by the attester 0x5598…2982usable until
Checking the signature in this browser.
- typed data
- the exact bytes a consumer verifies, as JSON
- attester
- 0x5598aa9146215bc13eb26f2c692ad1461fd32982
- signature
- 0x296a68a44c1acab74a35ecb3ee220cd2f28a215264aa95d10695cac37efb62e828aa2017f6d1fac3c65a0e3007e000e1c3d0580377412520edda9f9cf48d9ba21c
- question hash
- 0x5d1f03620071cbe198f8f8e70de7310f03006d852c6269f851c77f40d518817b
- answer type
- bytes32
- consumer
- none named; signed for the zero address
- scored
1 batch queuedon Ethereum mainnet
- scores
- settled, waiting for the batcher